158 related articles for article (PubMed ID: 29310836)
21. Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma.
Toraih EA; Ellawindy A; Fala SY; Al Ageeli E; Gouda NS; Fawzy MS; Hosny S
Biomed Pharmacother; 2018 Jun; 102():653-669. PubMed ID: 29604585
[TBL] [Abstract][Full Text] [Related]
22. High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.
Li C; Cui Y; Liu LF; Ren WB; Li QQ; Zhou X; Li YL; Li Y; Bai XY; Zu XB
Clin Genitourin Cancer; 2017 Oct; 15(5):570-576. PubMed ID: 28648755
[TBL] [Abstract][Full Text] [Related]
23. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
24. MALAT1 might be a predictive marker of poor prognosis in patients who underwent radical resection of middle thoracic esophageal squamous cell carcinoma.
Cao X; Zhao R; Chen Q; Zhao Y; Zhang B; Zhang Y; Yu J; Han G; Cao W; Li J; Chen X
Cancer Biomark; 2015; 15(6):717-23. PubMed ID: 26406400
[TBL] [Abstract][Full Text] [Related]
25. MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer.
Wang Y; Zhou Y; Yang Z; Chen B; Huang W; Liu Y; Zhang Y
Tumour Biol; 2017 Jul; 39(7):1010428317690998. PubMed ID: 28675122
[TBL] [Abstract][Full Text] [Related]
26. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer.
Liu T; Zhang X; Gao S; Jing F; Yang Y; Du L; Zheng G; Li P; Li C; Wang C
Oncotarget; 2016 Dec; 7(51):85551-85563. PubMed ID: 27888803
[TBL] [Abstract][Full Text] [Related]
27. Long non-coding RNA MALAT1 expression in patients with gestational diabetes mellitus.
Zhang Y; Wu H; Wang F; Ye M; Zhu H; Bu S
Int J Gynaecol Obstet; 2018 Feb; 140(2):164-169. PubMed ID: 29110299
[TBL] [Abstract][Full Text] [Related]
28. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA MVIH is associated with poor prognosis and malignant biological behavior in breast cancer.
Lei B; Xu SP; Liang XS; Li YW; Zhang JF; Zhang GQ; Pang D
Tumour Biol; 2016 Apr; 37(4):5257-64. PubMed ID: 26555546
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the expression profile of long non-coding RNAs MALAT1 and THRIL in children with immune thrombocytopenia.
Ayoub SE; Hefzy EM; Abd El-Hmid RG; Ahmed NA; Khalefa AA; Ali DY; Ali MA
IUBMB Life; 2020 Sep; 72(9):1941-1950. PubMed ID: 32563217
[TBL] [Abstract][Full Text] [Related]
31. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression.
Cho SF; Chang YC; Chang CS; Lin SF; Liu YC; Hsiao HH; Chang JG; Liu TC
BMC Cancer; 2014 Nov; 14():809. PubMed ID: 25369863
[TBL] [Abstract][Full Text] [Related]
32. The Plasma LncRNA Acting as Fingerprint in Hilar Cholangiocarcinoma.
Shi J; Li X; Zhang F; Kong L; Zhang X; Cheng Y; Guan Q; Cao X; Zhu W; Ou K; Chen Q; Hu S
Cell Physiol Biochem; 2018; 49(5):1694-1702. PubMed ID: 30231247
[TBL] [Abstract][Full Text] [Related]
33. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
Özgür E; Ferhatoğlu F; Şen F; Saip P; Gezer U
Cancer Biomark; 2020; 27(1):11-17. PubMed ID: 31640083
[TBL] [Abstract][Full Text] [Related]
34. The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer.
Ke D; Li H; Zhang Y; An Y; Fu H; Fang X; Zheng X
Oncotarget; 2017 Mar; 8(13):21516-21525. PubMed ID: 28423525
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma.
Handa H; Kuroda Y; Kimura K; Masuda Y; Hattori H; Alkebsi L; Matsumoto M; Kasamatsu T; Kobayashi N; Tahara KI; Takizawa M; Koiso H; Ishizaki T; Shimizu H; Yokohama A; Tsukamoto N; Saito T; Murakami H
Br J Haematol; 2017 Nov; 179(3):449-460. PubMed ID: 28770558
[TBL] [Abstract][Full Text] [Related]
36. Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects.
Han L; Ma P; Liu SM; Zhou X
Tumour Biol; 2016 May; 37(5):6847-54. PubMed ID: 26662314
[TBL] [Abstract][Full Text] [Related]
37. Unleash multifunctional role of long noncoding RNAs biomarker panel in breast cancer: a predictor classification model.
Toraih EA; El-Wazir A; Ageeli EA; Hussein MH; Eltoukhy MM; Killackey MT; Kandil E; Fawzy MS
Epigenomics; 2020 Jul; 12(14):1215-1237. PubMed ID: 32812439
[No Abstract] [Full Text] [Related]
38. Long non-coding RNA MALAT1 is an independent prognostic factor of osteosarcoma.
Gao KT; Lian D
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3561-5. PubMed ID: 27649655
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
Meseure D; Vacher S; Lallemand F; Alsibai KD; Hatem R; Chemlali W; Nicolas A; De Koning L; Pasmant E; Callens C; Lidereau R; Morillon A; Bieche I
Br J Cancer; 2016 Jun; 114(12):1395-404. PubMed ID: 27172249
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study.
Xu N; Chen F; Wang F; Lu X; Wang X; Lv M; Lu C
Tumour Biol; 2015 Sep; 36(10):7659-65. PubMed ID: 25929808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
